- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | AirSculpt anticipates $12M-$14M adjusted EBITDA while rolling out AlloClae partnership | 2 | Seeking Alpha | ||
| 10.08. | Airsculpt Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 10.08. | AirSculpt Technologies Aktie bricht nach enttäuschenden Zahlen und Prognosesenkung ein | 3 | Investing.com Deutsch | ||
| 10.08. | AirSculpt Technologies Non-GAAP EPS of $0.01, revenue of $42.9M; reaffirms FY 2026 outlook | 1 | Seeking Alpha | ||
| AIRSCULPT TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 10.08. | Airsculpt Technologies, Inc.: AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results | 651 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| 10.08. | Airsculpt Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Airsculpt Technologies: BTIG bleibt bei "Neutral"-Einstufung | 3 | Investing.com Deutsch | ||
| 18.05. | Airsculpt Technologies stock rating held at Neutral by BTIG | 1 | Investing.com | ||
| 08.05. | Airsculpt Technologies, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | AirSculpt outlines 2026 revenue of $151M-$157M while targeting sequential improvement in Q2 | 1 | Seeking Alpha | ||
| 08.05. | Airsculpt Technologies, Inc.: AirSculpt Technologies Reports First Quarter Fiscal 2026 Results | 553 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| 08.05. | Airsculpt Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | Airsculpt Technologies, Inc.: AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results | 323 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| 17.11.25 | Airsculpt Technologies, Inc.: AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board | 461 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| 07.11.25 | Airsculpt Technologies, Inc.: AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results | 725 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,698 | +1,29 % | Piper Sandler raises Teladoc stock price target on BetterHelp growth | ||
| SERNOVA BIOTHERAPEUTICS | 0,065 | -0,61 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 1,420 | -2,61 % | Cerenome completes enrollment in glioblastoma drug trial | ||
| ATOSSA THERAPEUTICS | 2,120 | +8,72 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 17,000 | -3,95 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,371 | +0,52 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 11,630 | -1,90 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,100 | 0,00 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 6,180 | +4,57 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 3,840 | -3,76 % | Clover Health im Aufwind: Needham startet Coverage mit "Buy" und Kursziel von 6 Dollar | ||
| SENSEONICS | 8,000 | -5,88 % | Senseonics Holdings, Inc.: Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component | ||
| NANO-X IMAGING | 0,327 | 0,00 % | NANO-X IMAGING LTD: TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI's AVC Solution | ||
| TEMPEST THERAPEUTICS | 0,478 | -4,42 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| IMUNON | 0,780 | 0,00 % | Imunon, Inc. - S-1, General form for registration of securities |
AIRSCULPT TECHNOLOGIES INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,720 Euro und damit 0,00 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AIRSCULPT TECHNOLOGIES INC finden Sie auf Wallstreet Online.